Segment disclosures

Company overview

Precision BioSciences, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

9 dimension combinations 74 retained observations 26 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Food Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dtil:FoodSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-313806000 USD20220315Open filing evidence
2020-01-01 – 2020-12-312422000 USD20220315Open filing evidence
2019-01-01 – 2019-12-311606000 USD20210318Open filing evidence
2018-01-01 – 2018-12-311360000 USD20200310Open filing evidence

Operating Segments · Therapeutics Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=dtil:TherapeuticsSegmentMember
PeriodValueUnitFiledEvidence
2021-01-01 – 2021-12-31111723000 USD20220315Open filing evidence
2020-01-01 – 2020-12-3121863000 USD20220315Open filing evidence
2019-01-01 – 2019-12-3120632000 USD20210318Open filing evidence
2018-01-01 – 2018-12-319523000 USD20200310Open filing evidence

Food Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=ck0001357874:FoodSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-03-31643000 USD20190429Open filing evidence
2018-01-01 – 2018-03-3181000 USD20190429Open filing evidence

Therapeutics Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=ck0001357874:TherapeuticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2019-01-01 – 2019-03-314819000 USD20190429Open filing evidence
2018-01-01 – 2018-03-311447000 USD20190429Open filing evidence

Food Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=dtil:FoodSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-301241000 USD20211110Open filing evidence
2021-01-01 – 2021-09-302829000 USD20211110Open filing evidence
2021-04-01 – 2021-06-30918000 USD20210812Open filing evidence
2021-01-01 – 2021-06-301588000 USD20210812Open filing evidence
2021-01-01 – 2021-03-31670000 USD20210513Open filing evidence
2020-07-01 – 2020-09-30315000 USD20211110Open filing evidence
2020-01-01 – 2020-09-301898000 USD20211110Open filing evidence
2020-04-01 – 2020-06-3058000 USD20210812Open filing evidence
2020-01-01 – 2020-06-301583000 USD20210812Open filing evidence
2020-01-01 – 2020-03-311525000 USD20210513Open filing evidence
2019-07-01 – 2019-09-30146000 USD20201110Open filing evidence
2019-01-01 – 2019-09-301359000 USD20201110Open filing evidence
2019-04-01 – 2019-06-30570000 USD20200813Open filing evidence
2019-01-01 – 2019-06-301213000 USD20200813Open filing evidence
2019-01-01 – 2019-03-31643000 USD20200515Open filing evidence
2018-07-01 – 2018-09-30426000 USD20191112Open filing evidence
2018-01-01 – 2018-09-30934000 USD20191112Open filing evidence
2018-04-01 – 2018-06-30427000 USD20190814Open filing evidence
2018-01-01 – 2018-06-30508000 USD20190814Open filing evidence

Food Segment · Operating Segments · Change

Statement Business Segments · Consolidation Items · Change In Accounting Estimate By Type

Source dimensions us-gaap:StatementBusinessSegmentsAxis=dtil:FoodSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ChangeInAccountingEstimateByTypeAxis=dtil:ChangeMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2020-09-30169000 USD20201110Open filing evidence
2020-01-01 – 2020-09-30539000 USD20201110Open filing evidence
2020-04-01 – 2020-06-30-512000 USD20200813Open filing evidence
2020-01-01 – 2020-06-30370000 USD20200813Open filing evidence

Operating Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=dtil:OperatingSegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261103Open filing evidence
2026-01-01 – 2026-09-3010838000 USD20261103Open filing evidence
2026-04-01 – 2026-06-300 USD20260806Open filing evidence
2026-01-01 – 2026-06-3010838000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3110838000 USD20260505Open filing evidence
2025-01-01 – 2025-12-3134264000 USD20260312Open filing evidence
2025-07-01 – 2025-09-3013000 USD20261103Open filing evidence
2025-01-01 – 2025-09-3060000 USD20261103Open filing evidence
2025-04-01 – 2025-06-3018000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3047000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3129000 USD20260505Open filing evidence
2024-01-01 – 2024-12-3168696000 USD20260312Open filing evidence
2024-07-01 – 2024-09-30576000 USD20251103Open filing evidence
2024-01-01 – 2024-09-3068058000 USD20251103Open filing evidence
2024-04-01 – 2024-06-3049898000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3067482000 USD20250807Open filing evidence

Therapeutics Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=dtil:TherapeuticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2021-07-01 – 2021-09-3022795000 USD20211110Open filing evidence
2021-01-01 – 2021-09-30106361000 USD20211110Open filing evidence
2021-04-01 – 2021-06-3067887000 USD20210812Open filing evidence
2021-01-01 – 2021-06-3083566000 USD20210812Open filing evidence
2021-01-01 – 2021-03-3115679000 USD20210513Open filing evidence
2020-07-01 – 2020-09-307048000 USD20211110Open filing evidence
2020-01-01 – 2020-09-3013541000 USD20211110Open filing evidence
2020-04-01 – 2020-06-301020000 USD20210812Open filing evidence
2020-01-01 – 2020-06-306493000 USD20210812Open filing evidence
2020-01-01 – 2020-03-315473000 USD20210513Open filing evidence
2019-07-01 – 2019-09-304719000 USD20201110Open filing evidence
2019-01-01 – 2019-09-3014357000 USD20201110Open filing evidence
2019-04-01 – 2019-06-304819000 USD20200813Open filing evidence
2019-01-01 – 2019-06-309638000 USD20200813Open filing evidence
2019-01-01 – 2019-03-314819000 USD20200515Open filing evidence
2018-07-01 – 2018-09-302115000 USD20191112Open filing evidence
2018-01-01 – 2018-09-305009000 USD20191112Open filing evidence
2018-04-01 – 2018-06-301447000 USD20190814Open filing evidence
2018-01-01 – 2018-06-302894000 USD20190814Open filing evidence

Therapeutics Segment · Operating Segments · Change

Statement Business Segments · Consolidation Items · Change In Accounting Estimate By Type

Source dimensions us-gaap:StatementBusinessSegmentsAxis=dtil:TherapeuticsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:ChangeInAccountingEstimateByTypeAxis=dtil:ChangeMember
PeriodValueUnitFiledEvidence
2020-07-01 – 2020-09-302329000 USD20201110Open filing evidence
2020-01-01 – 2020-09-30-816000 USD20201110Open filing evidence
2020-04-01 – 2020-06-30-3799000 USD20200813Open filing evidence
2020-01-01 – 2020-06-30-3145000 USD20200813Open filing evidence